formoterol fumarate / Generic mfg. - LARVOL DELTA

Superficial Laryngeal Nerve Block for Neurogenic Cough (AAAAI-WAO 2025) - "She failed improvement 5 months of Dupixent, nebulized Perforomist and budesonide, 4 weeks of 30mg daily prednisone, high-dose PPI and 100mg of nortriptyline daily. Conclusions This is the first allergy case report of neurogenic cough treated with SLNB. Allergist should be aware that patients with refractory cough may benefit from this novel therapy."

Asthma • Chronic Cough • Cough • Dysphonia • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sarcoidosis

Comparison table: Inhaled drugs for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Aucta announces FDA approval of a generic version of Perforomist (Formoterol Fumarate) Inhalation Solution (PRNewswire) - "Aucta Pharmaceuticals...announced today the U.S. approval of a generic version of Perforomist® (formoterol fumarate) Inhalation Solution....'We are pleased to have our third Aucta Pharmaceuticals-developed product approved for the U.S. market. This marks the launch of our new commercial infrastructure to commercialize this and future products in the U.S.'"

ANDA • Chronic Obstructive Pulmonary Disease

Lupin launches Formoterol Fumarate Inhalation Solution in US market (Business Standard) - "Lupin announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equival...Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of USD 268 million in the U. S."

Generic launch • Sales • Chronic Obstructive Pulmonary Disease

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: University of Tennessee Graduate School of Medicine | Trial completion date: Apr 2022 ➔ Mar 2023 | Trial primary completion date: Apr 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution (Lupin Pharmaceuticals Press Release) - "Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P."

ANDA • Chronic Obstructive Pulmonary Disease

ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Stanford University | Enrolling by invitation ➔ Recruiting | Trial primary completion date: Aug 2024 ➔ Jul 2025

Enrollment status • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - P3 | N=600 | Enrolling by invitation | Sponsor: Stanford University | Trial completion date: Jun 2024 ➔ Aug 2025 | Trial primary completion date: Apr 2024 ➔ Aug 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Alembic Pharma receives USFDA approval for Formoterol Fumarate Inhalation Solution (Business Standard) - "Alembic Pharmaceuticals today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial...twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema."

ANDA • Chronic Obstructive Pulmonary Disease

Teva Announces Its Launch of the First Generic PERFOROMIST, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States (Businesswire) - "Teva Pharmaceuticals...announced its U.S. launch of the first generic version of twice daily PERFOROMIST®, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema....Formoterol fumarate inhalation solution is only for use with a nebulizer."

Generic launch • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (clinicaltrials.gov) - P4; N=60; Recruiting; Sponsor: University of Tennessee Graduate School of Medicine; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Respiratory Diseases

Expanded table: Some inhaled drugs for treatment of asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Respiratory Diseases

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (clinicaltrials.gov) - P4; N=60; Not yet recruiting; Sponsor: University of Tennessee Graduate School of Medicine

Clinical • New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Infectious Disease • Tobacco Cessation

Comparison table: Inhaled long-acting bronchodilators for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease

ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - P3; N=600; Enrolling by invitation; Sponsor: Stanford University; Recruiting ➔ Enrolling by invitation

Enrollment status • Infectious Disease • Pneumonia • Respiratory Diseases

ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - P3; N=600; Recruiting; Sponsor: Stanford University; Not yet recruiting ➔ Recruiting; Trial completion date: Nov 2024 ➔ May 2024; Trial primary completion date: Sep 2024 ➔ Mar 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases